KOSDAQ Bio ETFs See Sharp Declines Amid Plunging Stock Prices
Exchange-traded funds (ETFs) investing in KOSDAQ-listed bio companies have experienced significant drops in returns, posing challenges for asset management firms. The sharp share price declines of key bio stocks such as Samchundang Pharm and ABL Bio were cited as primary factors. In particular, ABL Bio plummeted following news that its US partner's clinical trial had failed, which heavily impacted the performance of major bio ETFs like 'KoAct Biohealthcare Active,' 'HANARO Bio Korea Active,' 'TIGER Technology Transfer Bio Active,' and 'RISE Bio TOP10 Active.'
Concentration of portfolio allocations in specific stocks such as ABL Bio, Legochem Bio, and Olix among several ETFs has further amplified the losses. The downturn has become especially pronounced over the past week, resulting in a substantial deterioration of these ETFs' profitability. Asset managers are attempting portfolio rebalancing strategies to stem losses, but meaningful improvements remain elusive. Industry experts warn that a short-term turnaround appears unlikely, stressing the need for cautious risk management in the highly volatile bio sector.
Related ETF
Related News
Samchundang and ABL Shock... Bioactive ETF PlummetsSamchundang and ABL Shock... Bioactive ETF Plummets, Limited Stock Selection Hinders Profit Improvement
Stock Drops 19% in a Day... 'Following Samchundang Again' Retail Investor Shock - Korea Economic Daily19% drop in one day... Another shock for retail investors following Samchundang, Bio Active ETF performance ranks 1st to 4th lowest over the week
Related ETF
Another Shock Following Samchundang Pharm… Struggling 'Bio Active ETF' - Korea Economic DailyPlunged 19% in a day… Another shock for individual investors following Samchundang Pharm, Bio Active ETF records bottom 1 to 4 ranks in weekly returns
Related ETF